Journal article icon

Journal article

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity

Abstract:

Background: The development of a new, more effective vaccine against tuberculosis (TB) for use in healthy and HIV-infected adults, children and infants, remains a global health priority. MVA85A is a candidate tuberculosis vaccine designed to enhance immunity to the existing vaccine, Bacillus Calmette-Guerin (BCG). MVA85A entered clinical trials in 2002 and has now progressed to Phase IIb proof-of-concept efficacy trials in infants and HIV-infected adults in Africa. Methods: A detailed analysi...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's version

Actions


Access Document


Files:
Publisher copy:
10.1016/j.trivac.2012.07.001

Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, The Jenner Institute
Role:
Author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, The Jenner Institute
Role:
Author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, The Jenner Institute
Role:
Author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, The Jenner Institute
Role:
Author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, The Jenner Institute
Role:
Author
Expand authors...
More from this funder
Funding agency for:
McShane, H
University of Oxford More from this funder
Publisher:
Elsevier Publisher's website
Journal:
Trials in Vaccinology Journal website
Volume:
1
Pages:
27-35
Publication date:
2012-01-01
DOI:
EISSN:
1879-4378
ISSN:
1879-4378
URN:
uuid:cc0cb5a8-50e5-42b1-bc25-f499b0a76aac
Source identifiers:
350867
Local pid:
pubs:350867
Language:
English
Keywords:

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP